Infusion FAQs:

Who gets the infusions: Patients that have symptoms less than 10 days, are high risk with 3 risk factors, positive COVID-19 results, and whom are approved by the appointed scarce resource allocation committee. If you are determine to be of benefit from this treatment the infusion center team will contact you to schedule an appointment.

When: There are 8 available appointments Monday thru Friday. 4 in the morning and 4 in the afternoon

How long does it take: approximately 3 hours, this includes registration, infusion time, observation time and check out

Where: Baptist Medical Center Outpatient Infusion Center. Hills Breast Center. 2nd floor. Downtown Jax (across from MD Anderson)

Costs: Unknown but if you are determined by the committee that you need the infusion, they will go over this with you. Those without insurance are also receiving the infusion regardless of insurance status.

Why: Antibodies may limit the amount of virus in the body, decrease duration, severity of COVID-19 infection, and likelihood of hospitalization

FDA status: authorized for emergency use by the FDA

Does it have the virus in it: No. It contains man-made antibodies (similar to the antibodies from patients that recovered from COVID-19)

SIDE EFFECTS: Infusion-related reactions have been observed with administration of bamlanivimab. Signs and symptoms of infusion related reactions may include: fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, dizziness.

Table 2: Treatment-emergent Adverse Events Reported in at Least 1% of All Subjects in BLAZE-1

Preferred term	Placebo N=156 %	Bamlanivimab			
		700 mg N=101 %	2,800 mg N=107 %	7,000 mg N=101 %	Total N=309 %
Nausea	4%	3%	4%	5%	4%
Diarrhea	5%	1%	2%	7%	3%
Dizziness	2%	3%	3%	3%	3%
Headache	2%	3%	2%	0%	2%
Pruritus	1%	2%	3%	0%	2%
Vomiting	3%	1%	3%	1%	2%

Hypersensitivity Including Anaphylaxis and Infusion-related Reactions:
One anaphylaxis reaction and one serious infusion-related reaction were reported during infusion of bamlanivimab in ongoing, blinded trials. The infusions were stopped. Both reactions required treatment, one required epinephrine. Both events resolved.

Immediate non-serious hypersensitivity events were noted for 2% of bamlanivimab-treated subjects and 1% of placebo-treated subjects in BLAZE-1. Reported events of pruritus, flushing and hypersensitivity were mild with one case of face swelling which was moderate. All events resolved *[see Warnings and Precautions (5.1)]*.